Commure acquires digital care navigator Memora Health

Photo: Franco Vogt/Getty Images

Healthcare technology company Commure has acquired digital care navigation platform Memora Health for an undisclosed amount, the company recently announced.

Memora described itself as an "intelligent care enablement platform" that partners with health systems, health plans and digital health companies to incorporate AI-driven automation of high-touch clinical workflows.

The platform sends patient-reported concerns and data to clinical care team members and offers two-way communication and support, the company said.

Mountain View, California-based Commure, meanwhile, offers a suite of AI-powered technology. Their offerings range from ambient AI and staff-duress alerting to provider copilots, patient engagement tools and revenue cycle management automation.

WHAT'S THE IMPACT?

According to Commure, Memora will strengthen its existing portfolio of patient engagement, clinical documentation, revenue cycle management and RTLS technologies.

By integrating Memora's patient navigation tools with CommureOS's proprietary integration engine, Memora said the combined platform enables healthcare organizations to personalize patient-care pathways and drive improved clinical and operational outcomes.

The deal underscores Memora's commitment to harnessing a common data infrastructure across the health system, the company said.

"The acquisition of Memora Health is a significant step forward in our mission to simplify provider, patient, and administrator workflows," said Commure CEO Tanay Tandon. "By combining Memora's intelligent care navigation with Commure's existing solutions, we can deliver a seamless experience for providers and care teams, and enhance patient support throughout their healthcare journey."

THE LARGER TREND

Dr. Brit Berry-Pusey, chief operating officer for AI cancer-mapping startup Avenda Health, said that, while more and more companies and startups are advancing artificial intelligence in healthcare, being reimbursed for AI technologies has become challenging.

Currently, the way the approval process for new devices is set up, it can take a full seven years between FDA clearance and the time reimbursement is finally established.

"The FDA has learned a lot about how to regulate products, and the government has learned how to pay for AI products," said Berry-Pusey. "Unfortunately, the way reimbursement is set up in the U.S., it disincentivizes new technologies. If you're really pushing the boundaries and creating something novel, it means you have to start from scratch from a reimbursement perspective."

Jeff Lagasse is editor of Healthcare Finance News.
Email: jlagasse@himss.org
Healthcare Finance News is a HIMSS Media publication.